About Intercept Pharmaceuticals
Intercept Pharmaceuticals is a company based in New York (United States) founded in 2002 by Mark Pruzanski was acquired by Alfasigma in September 2023. Intercept Pharmaceuticals has raised $121 million across 5 funding rounds from investors including Orbimed, Alfasigma and Genextra. The company has 341 employees as of December 31, 2022. Intercept Pharmaceuticals offers products and services including FXR Agonist. Intercept Pharmaceuticals operates in a competitive market with competitors including NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others.
- Headquarter New York, United States
- Employees 341 as on 31 Dec, 2022
- Founders Mark Pruzanski
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Intercept Pharmaceuticals, Inc.
-
Annual Revenue
$285.71 M (USD)10as on Dec 31, 2022
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$121 M (USD)
in 5 rounds
-
Latest Funding Round
$500 M (USD), Post-IPO
Aug 01, 2021
-
Investors
Orbimed
& 4 more
-
Employee Count
341
as on Dec 31, 2022
-
Acquired by
Alfasigma
(Sep 26, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Intercept Pharmaceuticals
Intercept Pharmaceuticals offers a comprehensive portfolio of products and services, including FXR Agonist.
Treatment for primary biliary cholangitis liver disease
People of Intercept Pharmaceuticals
Unlock access to complete
Unlock access to complete
Leadership Team
61 people
Software Development Team
47 people
Operations Team
16 people
Product Management Team
9 people
Human Resources and Administration
5 people
Legal and Compliance
4 people
Head Team
4 people
Finance and Accounting
4 people
Unlock access to complete
Funding Insights of Intercept Pharmaceuticals
Intercept Pharmaceuticals has successfully raised a total of $121M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $500 million completed in August 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intercept Pharmaceuticals
Intercept Pharmaceuticals has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Orbimed, Alfasigma and Genextra.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
A holding company focused on life science investments is operated.
|
Locked | Locked | Locked | |
|
Manages investments and risks to deliver consistent returns for institutional investors.
|
Locked | Locked | Locked |
Investor details for Intercept Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intercept Pharmaceuticals
Investment portfolio details for Intercept Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Intercept Pharmaceuticals
Detailed financials for Intercept Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intercept Pharmaceuticals Comparisons
Peer comparison for Intercept Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intercept Pharmaceuticals
Intercept Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as NGM Biopharmaceuticals, Nimbus Therapeutics, Altimmune, Mirum Pharmaceuticals and Akero Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biologics are developed for cardio-metabolic and liver diseases.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics are developed for rare diseases treatment.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for metabolic disorders are developed.
|
|
| Locked | Locked | Locked |
Therapies for liver disease and cancer are developed.
|
Detailed competitors of Intercept Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intercept Pharmaceuticals
Complete news archive for Intercept Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intercept Pharmaceuticals
Intercept Pharmaceuticals was founded in 2002 and raised its 1st funding round 4 years after it was founded.
Intercept Pharmaceuticals is headquartered in New York, United States. It is registered at New York, New York, United States.
Intercept Pharmaceuticals is a funded company, having raised a total of $121M across 5 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Intercept Pharmaceuticals is 341.
Annual revenue of Intercept Pharmaceuticals is $285.71M as on Dec 31, 2022.
Developer of therapeutics to treat progressive non-viral liver diseases. It offers INT-747, an FXR modulating agent that treats patients with chronic liver diseases such as Nonalcoholic steatohepatitis (NASH), and Primary sclerosing cholangitis. FXR is a nuclear receptor expressed in the liver, intestine, kidney, and adipose tissue. FXR regulates a wide variety of target genes critically involved in the control of BA synthesis and transport, Lipid metabolism, and Glucose homeostasis.
Intercept Pharmaceuticals's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Madrigal Pharmaceuticals.
Intercept Pharmaceuticals offers FXR Agonist.
Intercept Pharmaceuticals has 5 investors. Key investors include Orbimed, Alfasigma, Genextra, Balyasny Asset Management, and JAFCO Group.